Max Unfried

13.4K posts

Max Unfried banner
Max Unfried

Max Unfried

@MaxUnfried

Man of Science 🧬 AI & Gerophysics to understand Aging. 🇸🇬 Rethinking the Fundamentals of Aging & Rejuvenation Biology @TTIScience 🇺🇸

Singapore & Europe Katılım Ekim 2018
1.1K Takip Edilen4.4K Takipçiler
Max Unfried retweetledi
Alexey Strygin
Alexey Strygin@strygah·
I'm helping organize Mirai, a pop-up city running this October at KBIC (Kobe Biomedical Innovation Cluster), with a focus on longevity biotech, medical devices, and human augmentation. @aubreydegrey, @adamgries, @realNathanCheng, @EleanorSheekey, and @cremieuxrecueil have already confirmed their presence. More big names are still in talks (TBA). 🇯🇵Japan has built some of the world's fastest regulatory pathways for cell and gene therapies, and for adjacent biotech and medtech too. The Mirai program includes in-person meetings with local regulators, research institutes, and biopharma companies, plus intros to local partners. This is for you if: - you're looking for cofounders, partners, or a job in the field; - you want to bring your product to the Japanese market; - you're hunting for cutting-edge Japanese therapies for your own market; - you want to spend a month among smart people in a cool country and learn a ton. Early-bird tickets are cheap: $399 (and even cheaper with my promo code "ALEXEY"). It does not include housing or food, though. I've attended and helped organize several events like this (Zuzalu, @ZelarCity, Viva Frontier Tower). Every one has been a great experience, and I can't recommend it enough!! We also have a great value offering for sponsors. DM me if you want to know more.
Alexey Strygin tweet media
English
3
12
45
15.7K
Eric Topol
Eric Topol@EricTopol·
@CharlesMBrenner @grok Brilliant. You might want to read the article before asking @grok But just ignore the results of 7 studies we reviewed
Eric Topol tweet media
English
5
1
9
2.2K
Charles Brenner, PhD
Charles Brenner, PhD@CharlesMBrenner·
@grok which is more likely: that some part of the human body rolls back its function from >70% expended to <25% expended between the ages of 60 and 70 versus people have taken conclusions from biomarker data that they don't fully understand and drawn absurd diagrams such as the one below
Eric Topol@EricTopol

An inflection point in medicine. Medicine is moving from calendars to clocks — from counting the years you've lived to measuring how fast you're aging. —It's not linear. —It's asynchronous, as seen by organs and cells in our body A "translation" of our review paper this week in the new Ground Truths Simplified image made with ChatGPT

English
5
2
39
13.4K
Max Unfried
Max Unfried@MaxUnfried·
There's currently no aging clock you can trust
English
5
1
15
916
Max Unfried retweetledi
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
The world's largest longevity biotechnology research & partnering event is coming to Boston. 13 years in the making, this will be the most impactful event we've ever produced with the highest-level speakers and sponsors. Massive thanks to Eli Lilly and specifically Andrew Adams (thanks to his work, the entire pharma industry is now focused on longevity), Ruth Gimeno, Daniel Skovronsky , Kunal Khanna, Berthil Clasen, PhD MBA, AstraZeneca and namely Mark Cobbold (thanks to him we moved to the epic Treehouse at Harvard), Jonathan Levi, Takeda, Christophe Weber, Phil McGurk and Morgan Stanley's Cailin McGurk, wonderful people at Abbvie, the pharma superstar, Elcin Barker Ergun of Menarini, the super-committed longevity scientists at BioAge (thanks Kristen Fortney), Fiona H. Marshall at Novartis, and the wonderful Barbara Cheifet of Nature Biotechnology. Top scientists from Novo Nordisk are also coming. The academic program and parallel forums will be absolutely top-notch - massively relevant to drug discovery. We basically went back to the drawing board and asked ourselves - "What do big pharma and startups need from the event to be more successful in partnering and advancing collaborations in R&D in longevity biotechnology? How do we accelerate the discovery and development of longevity therapeutics?" and the entire program is focused on these objectives - no irrelevant activities or people and super focused program designed to advance the field with big pharma requirements in mind. And again, I wanted to emphasize that this would not have happened without support from Eli Lilly. Without their sponsorship and participation in the event, we would not have been able to do it this year. Massive thanks to Vadim Gladyshev, Jesse Poganik , Morten Scheibye-Knudsen, Daniela Bakula, Evelyne Bischof, MD, PhD,Stephanie Tsang, Max Unfried - absolutely best co-organizers. linkedin.com/pulse/insilico…
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) tweet media
English
1
12
45
5.3K
Max Unfried retweetledi
Max Unfried
Max Unfried@MaxUnfried·
manifesting a first principles, physics-guided biology of aging
English
0
0
8
744
Max Unfried
Max Unfried@MaxUnfried·
How can one not be a fan of the Dionysian?
English
0
0
1
231
Max Unfried
Max Unfried@MaxUnfried·
The aging science and gerophysics community should really try to figure out why hazard ratio of supercentenarian seems to be constant? Is there a evolutionary argument to be made? Seems unlikely that selection pressure is at work. Is there a thermodynamic argument where entropy has reached a maximum? More damage does not matter anymore? A cheat code to the programed theory of aging? Lots to explore!
Nassim Nicholas Taleb@nntaleb

The Lindy technical paper is out, with comments on aging and immortality.

English
3
5
15
1.6K
Max Unfried retweetledi
Ivan Morgunov
Ivan Morgunov@EvanMorgun·
No disease is incurable. We just haven’t tried hard enough yet.
English
3
2
25
688
Max Unfried
Max Unfried@MaxUnfried·
People borrow "intelligence" from LLMs, pretending it is their own words. I do wonder what they feel: shame, embarrassment, anxious, guilt?
English
7
0
7
894
Max Unfried
Max Unfried@MaxUnfried·
1. AI companies hyping AI for drug development are doing it as they need a story 2. Spending 5% of the cost for computing on collecting real world data in a standardized manner would go a long way and is probably a better long term ROI then just scaling models.
Ihtesham Ali@ihtesham2005

Jennifer Doudna won the Nobel Prize for gene editing and went on Bloomberg to say the chatbots everyone is betting on cannot innovate at all. Every promise Silicon Valley is making about AI curing disease just hit the one person qualified to check it. She has spent her whole career inside the actual frontier of curing disease. So when she talks about what AI can and cannot do in biology, she is not guessing. She is reporting from inside the lab. Her words were blunt. She is not seeing chatbots innovate. They summarize data. They write reports. They do not come up with a brand new idea nobody has ever had. Then the interviewer pushed. So you're saying AI can't innovate? Doudna did not flinch. She does not know if it can't. She just does not see it doing it right now. This lands harder when you remember who is making the opposite case. Sam Altman says AI will eliminate disease within five years. Larry Ellison says AI will cure cancer in a 48 hour window. An OpenAI executive even floated that the company should get a cut of sales on any drug discovered through ChatGPT. Doudna answered that in two words. Good luck. Even the cancer specialists Altman is selling to keep warning that cancer is not one disease but hundreds, each needing its own cure, and that compute does not skip the years of lab work. Her reason is simpler. Biology is hard. You cannot simulate your way to an understanding of the human body. The people promising cures are the ones selling the tool. The person who actually won a Nobel building them is telling you it has not happened yet. Source: Bloomberg Originals Watch the full video on their official channel.

English
1
3
14
1.3K
Max Unfried
Max Unfried@MaxUnfried·
No single gene determines how long you life. Lifespan is a highly complex polygenic trait and we barely understand it. But we should certainly study long lived humans to understand it better.
Dave Asprey@daveasprey

New research suggests that how long you live may come down to a single gene. Scientists at Leiden University identified a variant in the CGAS gene that runs consistently in families who live significantly longer than average. The CGAS gene detects DNA fragments inside your cells and triggers an inflammatory response. People in these long-lived families had only one working copy of it, which means their baseline inflammatory response was lower. They lived longer and healthier lives. I've been saying this for years: chronic low-grade inflammation is one of the primary drivers of aging. Most people have way too much. Environmental toxins (especially mycotoxins), poor sleep, chronic stress, processed food, all of it creates the kind of cellular damage that keeps this pathway switched on. The researchers are right that you wouldn't want to suppress inflammation completely. You need a little bit of inflammation for a proper immune response and for healing. There are interventions that help modulate your inflammatory response without shutting it down: NAD precursors, curcumin, omega-3s, fixing sleep, cutting out seed oils, reducing stress. It probably isn't just one gene that influences lifespan. And this is a preprint that still needs peer review. But this research points clearly at a pathway that affects aging, and that pathway is something you can actually change. Better inputs, less stress, less inflammatory load.

English
3
0
21
1.8K
Max Unfried retweetledi
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
The world's largest and most important event in Longevity Biotechnology will take place at the DR Treehouse at Harvard and adjacent venues including the new Atlas hotel. This year, we will focus on real drug discovery and biotechnology with massive participation from the big pharma industry, investors, investment banks, and leading startups. Top academics with real drug discovery research will be speaking. Since we had to reduce the number of days from 5 to 3 we had to raise the bar.
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) tweet media
English
2
10
37
2.9K
Max Unfried
Max Unfried@MaxUnfried·
@LocasaleLab Neutral behaviour of scientists would be appropriate...but appropriateness has left the rooms
English
0
0
1
233
Jason Locasale
Jason Locasale@LocasaleLab·
This behavior doesn’t come out of nowhere. Scientific societies, journals, universities, and their lobbying and media arms have spent years taking political positions themselves. Scientists quickly learn that criticizing one political side is rewarded with approval, visibility, invitations, and career opportunities. If institutions funded by taxpayers function as political actors, they should not be surprised when elected officials begin questioning whether those institutions deserve continued funding.
Max Unfried@MaxUnfried

Kind of ridiculous that on academic conferences it is considered good style and behavior to talk shit and insult the current @WhiteHouse and @realDonaldTrump administration, on stage during what ought to be a scientific presentation.

English
5
7
89
6.1K